Form 4: TENAX Director Almenoff Acquires 30,000 Stock Options

TENAX THERAPEUTICS, INC. Director June Sherie Almenoff reported the acquisition of 30,000 stock options with an exercise price of $13.3, exercisable from January 9, 2027.

Summary

• Director June Sherie Almenoff reported changes in beneficial ownership of TENAX THERAPEUTICS, INC. securities.
• Acquired 30,000 stock options with an exercise price of $13.3 on January 9, 2026.
• These newly acquired options become exercisable on January 9, 2027, and have an expiration date of January 9, 2036.
• Holds indirect beneficial ownership of 1,993 shares of Common Stock through Meadowlark Management, LLC, disclaiming ownership except for pecuniary interest.
• Maintains existing direct beneficial ownership of additional stock options: 4 options at an exercise price of $3,200, 4 options at $992, 100,000 options at $5.94, and 80,000 options at $5.75.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally a positive signal, indicating confidence in the company's future. However, it's a routine compensation event rather than a direct investment of personal capital, hence a moderate positive score.

Positives

• A director acquiring new stock options can signal confidence in the company's future performance and strategic direction.
• The grant of 30,000 stock options aligns the director's financial interests with long-term shareholder value creation.

Future Outlook

The acquisition of new stock options by a director suggests an alignment of interests with long-term shareholder value creation, indicating a positive internal outlook on the company's future prospects.

Industry Context

Insider transactions, particularly option grants to directors, are common compensation practices in the biotechnology and pharmaceutical sectors like Tenax Therapeutics. These grants aim to incentivize leadership to achieve strategic milestones and enhance shareholder value, aligning their personal financial interests with the company's performance.

Comparison to Industry Standards

• The grant of 30,000 stock options to a director is a standard practice for incentivizing leadership in the biotech industry.
• While specific comparable companies or projects are not detailed in this filing, such grants are typically benchmarked against peer group compensation structures to ensure competitive and performance-aligned remuneration.

Related Party Transactions

• The reporting person disclaims beneficial ownership of 1,993 shares of Common Stock held indirectly by Meadowlark Management, LLC, except to the extent of her pecuniary interest therein.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's interests with shareholder value creation, potentially leading to more focused efforts on company performance.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director as part of their compensation. While it signals insider confidence, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Investors should 'hold' and await more substantive operational or financial updates.

Keywords

TENAX THERAPEUTICS, TENX, Stock Options, Insider Transaction, Form 4, Director Compensation, Beneficial Ownership, Equity Grant